Cite
HARVARD Citation
Takabayashi, T. et al. (2021). A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. American journal of rhinology & allergy. 35 (6), pp. 861-870. [Online].